Cargando…

Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus

AIMS: To determine whether blood glucose test strip (BGTS) utilization in patients with type 2 diabetes (T2D) is associated with the type of diabetes therapy, classified according to hypoglycemic risk. METHODS: A retrospective, longitudinal (2006–2012) study of Canadian private drug plans (PDP) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavares, Ruben, Duclos, Marc, Brabant, Marie-Josée, Checchin, Daniella, Bosnic, Nevzeta, Turvey, Katherine, Terres, Jorge Alfonso Ross
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877426/
https://www.ncbi.nlm.nih.gov/pubmed/26972690
http://dx.doi.org/10.1007/s00592-015-0823-z
_version_ 1782433372899901440
author Tavares, Ruben
Duclos, Marc
Brabant, Marie-Josée
Checchin, Daniella
Bosnic, Nevzeta
Turvey, Katherine
Terres, Jorge Alfonso Ross
author_facet Tavares, Ruben
Duclos, Marc
Brabant, Marie-Josée
Checchin, Daniella
Bosnic, Nevzeta
Turvey, Katherine
Terres, Jorge Alfonso Ross
author_sort Tavares, Ruben
collection PubMed
description AIMS: To determine whether blood glucose test strip (BGTS) utilization in patients with type 2 diabetes (T2D) is associated with the type of diabetes therapy, classified according to hypoglycemic risk. METHODS: A retrospective, longitudinal (2006–2012) study of Canadian private drug plans (PDP) and Ontario Public Drug Programs (OPDP) prescription claims was conducted. Analyses were restricted to patients with T2D with or without a claim for BGTS. Daily BGTS utilization (TS/patient/day) was evaluated by diabetes therapy classified by hypoglycemic risk. Multivariate analyses were conducted to identify determinants of BGTS utilization. RESULTS: The T2D cohort comprised 5,759,591 observations from 1,949,129 claimants. Mean BGTS utilization was 0.84 TS/patient/day and differed between PDP and OPDP (0.66 vs. 1.00). Daily utilization was greatest in patients receiving therapy associated with a pre-defined high risk of hypoglycemia [insulin: basal + bolus (2.16), premixed (1.65), basal (1.16), other insulin regimens (2.13), and sulfonylureas (0.74)] versus non-sulfonylurea non-insulin-based regimens (0.52). For non-insulin therapy, BGTS utilization was greater for patients on multiple non-insulin therapies versus monotherapy (0.74 vs. 0.53 TS/patient/day). In multivariate analyses, drivers for BGTS utilization included insulin use, previous BGTS use, and female gender. Previous diabetes therapy and duration of therapy were negatively correlated with BGTS utilization. CONCLUSIONS: BGTS utilization varies depending on the type of therapy used to treat T2D according to hypoglycemic risk. Decision making regarding BGTS needs to account for robust analyses of current utilization and its value in those settings, including in patients not receiving diabetes therapy and the prevalence of circumstances conducive to more intensive monitoring.
format Online
Article
Text
id pubmed-4877426
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-48774262016-06-21 Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus Tavares, Ruben Duclos, Marc Brabant, Marie-Josée Checchin, Daniella Bosnic, Nevzeta Turvey, Katherine Terres, Jorge Alfonso Ross Acta Diabetol Original Article AIMS: To determine whether blood glucose test strip (BGTS) utilization in patients with type 2 diabetes (T2D) is associated with the type of diabetes therapy, classified according to hypoglycemic risk. METHODS: A retrospective, longitudinal (2006–2012) study of Canadian private drug plans (PDP) and Ontario Public Drug Programs (OPDP) prescription claims was conducted. Analyses were restricted to patients with T2D with or without a claim for BGTS. Daily BGTS utilization (TS/patient/day) was evaluated by diabetes therapy classified by hypoglycemic risk. Multivariate analyses were conducted to identify determinants of BGTS utilization. RESULTS: The T2D cohort comprised 5,759,591 observations from 1,949,129 claimants. Mean BGTS utilization was 0.84 TS/patient/day and differed between PDP and OPDP (0.66 vs. 1.00). Daily utilization was greatest in patients receiving therapy associated with a pre-defined high risk of hypoglycemia [insulin: basal + bolus (2.16), premixed (1.65), basal (1.16), other insulin regimens (2.13), and sulfonylureas (0.74)] versus non-sulfonylurea non-insulin-based regimens (0.52). For non-insulin therapy, BGTS utilization was greater for patients on multiple non-insulin therapies versus monotherapy (0.74 vs. 0.53 TS/patient/day). In multivariate analyses, drivers for BGTS utilization included insulin use, previous BGTS use, and female gender. Previous diabetes therapy and duration of therapy were negatively correlated with BGTS utilization. CONCLUSIONS: BGTS utilization varies depending on the type of therapy used to treat T2D according to hypoglycemic risk. Decision making regarding BGTS needs to account for robust analyses of current utilization and its value in those settings, including in patients not receiving diabetes therapy and the prevalence of circumstances conducive to more intensive monitoring. Springer Milan 2016-03-14 2016 /pmc/articles/PMC4877426/ /pubmed/26972690 http://dx.doi.org/10.1007/s00592-015-0823-z Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Tavares, Ruben
Duclos, Marc
Brabant, Marie-Josée
Checchin, Daniella
Bosnic, Nevzeta
Turvey, Katherine
Terres, Jorge Alfonso Ross
Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus
title Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus
title_full Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus
title_fullStr Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus
title_full_unstemmed Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus
title_short Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus
title_sort differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877426/
https://www.ncbi.nlm.nih.gov/pubmed/26972690
http://dx.doi.org/10.1007/s00592-015-0823-z
work_keys_str_mv AT tavaresruben differencesinselfmonitoredbloodglucoseteststriputilizationbytherapyfortype2diabetesmellitus
AT duclosmarc differencesinselfmonitoredbloodglucoseteststriputilizationbytherapyfortype2diabetesmellitus
AT brabantmariejosee differencesinselfmonitoredbloodglucoseteststriputilizationbytherapyfortype2diabetesmellitus
AT checchindaniella differencesinselfmonitoredbloodglucoseteststriputilizationbytherapyfortype2diabetesmellitus
AT bosnicnevzeta differencesinselfmonitoredbloodglucoseteststriputilizationbytherapyfortype2diabetesmellitus
AT turveykatherine differencesinselfmonitoredbloodglucoseteststriputilizationbytherapyfortype2diabetesmellitus
AT terresjorgealfonsoross differencesinselfmonitoredbloodglucoseteststriputilizationbytherapyfortype2diabetesmellitus